Jagsonpal Pharmaceuticals Limited has informed the Exchange about regarding notice of Postal Ballot relating to Approval for buy-back of up to 16,00,000 fully paid-up equity shares of face value ₹2/- each at a price of ₹250/- per share, for an aggregate amount not exceeding ₹40 crores.
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty Microcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jagsonpal Pharmaceuticals has sent a postal ballot notice to shareholders seeking approval for a buyback of up to 16,00,000 fully paid-up equity shares (2.39% of paid-up capital) at ₹250 per share, for an aggregate amount not exceeding ₹40 crores. The buyback will be carried out through the tender offer route via the stock exchange, with promoters and promoter group not participating. The company has appointed Centrum Capital Limited as the manager to the buyback. Voting opens on March 26, 2026 and closes on April 24, 2026, with results to be announced within two working days thereafter. The company stated it is debt-free, has ₹176 crores of free cash as of December 31, 2025, and that the buyback is expected to improve ROCE by about 400 basis points.
This buyback is a positive signal for shareholders as the company is returning surplus cash, reflecting strong financial health and a shareholder-friendly capital allocation approach. Approval and execution could provide short-term price support and improve return ratios, though the relatively small size (2.39% of capital, ₹40 crores) limits the overall market impact.